Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Lademirsen (Primary)
- Indications Hereditary nephritis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms HERA
- Sponsors Regulus Therapeutics; Sanofi
- 13 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 24 Feb 2022 According to a Regulus Therapeutics media release, the company expects results in the first half of 2023.
- 09 Feb 2022 Status changed from recruiting to active, no longer recruiting.